HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...

Highly effective treatments for HIV have existed since the mid-1990s. But while these treatments keep people healthy, we do not yet have a safe and scalable way to completely rid the body of the virus ...

Gilead is committed to designing trials to help understand how HIV treatment and prevention impact populations that have been ...

Up-to-date clinical data is essential for ongoing research and treatment evaluations ... from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company ...

Although sexually transmitted infections are still at an epidemic level in the U.S., scientists at the CDC are expressing ...

Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

Data from the Centers for Disease Control and Prevention released Tuesday shows meaningful declines in STI rates between 2022 ...

A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

The epidemic of sexually transmitted infections (STIs) in the United States appears to be cooling off after more than two ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

New guidelines for diabetes treatment, mpox research, and healthcare system improvements discussed in comprehensive health ...